Stock & Company Details
Royalty Pharma plc $RPRX
Price:
46,691,331
443M
$25B
52 Week High:
$66.15
10 Day Average Volume:
42,760,466
16.25
50 Day Moving Average:
$156.49
52 Week Low:
$43.74
30 Day Average Volume:
49,506,373
$4.94
2021-02-05
0.95
30 Day Change:
13%
3 Month Change:
-0.32%
Health Technology
RPRX technical indicators
Latest Royalty Pharma plc (RPRX) technical indicators as of 2026-07-01: RSI, MACD, moving averages (SMA & EMA), Bollinger Bands, Stochastic, ADX, ATR, CCI, OBV and ROC.
RSI 14:
56.63 2.7%
MACD:
0.75 1.3%
SMA 50:
$53.07 0.2%
SMA 200:
$44.08 0.2%
EMA 20:
$54.87 0.2%
Bollinger Bands:
56.91 / 53.02
Stochastic:
85.33 6.8%
ADX 14:
31.50 4.2%
ATR 14:
1.38 2.3%
CCI 20:
80.08 46.5%
OBV:
331.61M 0.8%
ROC 12:
1.66% 17.6%
Select a strategy to see its performance
Backtested on this stock over recent history.
| Strategy | Trend | Return | Win rate |
|---|---|---|---|
| MACD Momentum Momentum Buy when MACD turns positive (crosses above zero) and RSI confirms momentum above 50; sell when MACD falls back below zero. | – | – | |
| RSI Reversal Mean reversion Buy when RSI falls below 30 (oversold), sell when it climbs above 70 (overbought). | – | – | |
| Volatility Breakout Volatility Buy when price closes above the upper Bollinger Band, sell on reversion to the 20-day average. | – | – | |
| Strong-Trend Pullback Trend + timing In strongly trending stocks (ADX above 25), buy short-term dips (Stochastic below 30) and sell into overbought (above 80). | – | – |
Overview
Royalty Pharma PLC is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. The company assembles a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry's therapies, which includes royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica, Astellas and Pfizer's Xtandi, Biogen's Tysabri, Johnson & Johnson's Tremfya, Gilead's Trodelvy, Merck's Januvia, Novartis' Promacta, Vertex's Kalydeco, Orkambi, Symdeko and Trikafta, and ten development-stage product candidates.
Finance Bot
Ask your questions
Start by typing a question below.
